Neuroscience/Neurology

Displaying 1 - 10 of 23


Small Molecule Theraputics That Target the Muscarinic Acetylcholine Receptor 1 For The Treatment of Alzheimer's Disease

The Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) has a mission to promote the translation of advances in basic science towards novel therapeutics. They have recruited faculty and staff with experience at over 10 different pharmaceutical companies to ensure a diverse set of approaches, techniques and philosophies to advancing compounds. Together they aim to de-risk drug discovery programs.


Licensing Contact

Tom Utley

615.343.3852
Therapeutics
Neuroscience/Neurology

Natural product for seizure relief and long term disease modification in Dravet Syndrome

Dravet syndrome is a lifelong form of epilepsy beginning in early childhood. Children with Dravet syndrome suffer aggressive seizures, impaired cognition, and an increased risk of premature death. Dravet syndrome does not respond to conventional anti-epileptic drugs, and current treatment regimens fail to fully elevate seizures. No disease modifying treatments exist. Researchers at Vanderbilt University have discovered a novel application of a known natural product in treating Dravet syndrome. This natural product could be beneficial to children suffering from Dravet syndrome in both reducing seizures and treating the underlying disease cause.


Licensing Contact

Tom Utley

615.343.3852

Inventors

Jingqiong Kang
Therapeutics
Neuroscience/Neurology

MemoryMonitor: A real-time neuroscientific learning monitor that knows whether you will later remember something you see

We all wish that we could know if we were going to later remember something, the moment that new information enters our brain. For example, if we could predict whether our children would later remember a vocabulary word, then we could have them spend more time on the words they will not remember. A group of neuroscientists at Vanderbilt University has developed a way of measuring and analyzing brain activity that achieves this goal of predicting later memory as we study and view new information. The procedure involves measuring brainwaves from just two electrodes on the head as people view pictures, words, or virtually any kind of information that a person hopes to remember later.


Licensing Contact

Masood Machingal

615.343.3548

Endonasal Surgical Robot for Sinus and Neurosurgery

Vanderbilt engineers have developed a robotic system for performing sinus and neurosurgery through the nose. This provides a less invasive way to access surgical sites in the sinuses and near the middle of the patient's head, leading to faster recovery times. The robot is modular and sterilizable with detachable cartridge-based instruments. Each instrument is a concentric tube robot, which is a needle-sized tool that can bend and elongate. The system delivers four of these instruments through a single nostril.


Licensing Contact

Ashok Choudhury

615.322.2503

Small Molecule mGlu5 NAMs For The Treatment of Depressive Disorders or Parkinson's Disease

The Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) has a mission to promote the translation of advances in basic science towards novel therapeutics. They have recruited faculty and staff with experience at over 10 different pharmaceutical companies to ensure a diverse set of approaches, techniques and philosophies to advancing compounds. Together they aim to de-risk drug discovery programs.


Licensing Contact

Tom Utley

615.343.3852

Small Molecule mGlu3 NAMs as Therapeutics for CNS Disorders

The Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) has a mission to promote the translation of advances in basic science towards novel therapeutics. They have recruited faculty and staff with experience at over 10 different pharmaceutical companies to ensure a diverse set of approaches, techniques and philosophies to advancing compounds. Together they aim to de-risk drug discovery programs.


Licensing Contact

Tom Utley

615.343.3852
Therapeutics

mGlu3 NAMs as Therapeutics for Chemoresistant Tumors

Targeting metabotropic glutamate receptor 3 (mGlu3) has been linked as a potential therapeutic to many neurological disorders and well as oncology through the use of dual specific mGlu2/3 Antagonists (LY341495, RO4491533, MGS0039, RO4988546).


Licensing Contact

Tom Utley

615.343.3852
Therapeutics

GluN2B Floxed Mice (also called NR2B, glutamate receptor 2B)

Allows for targeted deletion of the GluN2B subunit of NMDA receptors in specific cells or at specific times during development, juvenile, or adult stages. C57BL6/J background


Licensing Contact

Jody Hankins

615.322.5907

Inventors

Eric Delpire
Research Tools
Animal Model
Neuroscience/Neurology

Inhibitors of Inward-Rectifying Potassium Channels (Insecticide)

This research targets IRK.


Licensing Contact

Tom Utley

615.343.3852

HEK293 Cell Line with Stable Expression of Drosophila Serotonin Re-Uptake Transporter

This research targets SERT.


Licensing Contact

Karen Rufus

615.322.4295
Research Tools
Cell Line
Neuroscience/Neurology